In phase 1a, 2 TEAEs (adrenal insufficiency and hepatocellular injury) led to the discontinuation of pembrolizumab treatment, while in phase 1b, another patient had 2 TEAEs that led to the discontinuation of pembrolizumab (alanine transaminase increased and aspartate transaminase increased). Here, GPT is linked to Adrenal insufficiency.